Samuraciclib hydrochloride hydrate

• CAT Number: I043601
• Molecular Formula: C22H33ClN6O2
• Molecular Weight: 552.33
• Purity: ≥95%
• IUPAC Name: (3R,4R)-4-[[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol;hydrate;hydrochloride
• InChI: InChI=1S/C22H30N6O.ClH.H2O/c1-15(2)18-13-26-28-21(25-11-16-6-4-3-5-7-16)10-20(27-22(18)28)24-12-17-8-9-23-14-19(17)29;;/h3-7,10,13,15,17,19,23,25,29H,8-9,11-12,14H2,1-2H3,(H,24,27);1H;1H2/t17-,19+;;/m1../s1
• InChIKey: VOOZNVVXLBVUOZ-QFZUCXBQSA-N
• SMILES: CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)NC[C@H]4CCNC[C@@H]4O.O.Cl

Samuraciclib hydrochloride hydrate（Cat No.:I043601）is a potent, selective inhibitor of cyclin-dependent kinase 7 (CDK7), an enzyme that plays a critical role in regulating the cell cycle, transcription, and RNA processing. By inhibiting CDK7, Samuraciclib disrupts these essential cellular processes, leading to cell cycle arrest and apoptosis, particularly in rapidly dividing cancer cells. This compound is being studied for its potential therapeutic applications in oncology, especially for cancers that are driven by dysregulated transcription and cell cycle progression. Samuraciclib’s targeted mechanism of action offers promise as a treatment for various solid tumors and hematologic cancers.